NCT06182761View on ClinicalTrials.gov

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2028

Conditions
NSCLC
Interventions
DRUG

Sunvozertinib combination with Anlotinib

Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER